Description

Vaccines against the arthropod-borne dengue virus (DENV) are still commercially nonexistent. A subunit immunization strategy may be of value, especially if a safe viral vector acts as a biologically active

Vaccines against the arthropod-borne dengue virus (DENV) are still commercially nonexistent. A subunit immunization strategy may be of value, especially if a safe viral vector acts as a biologically active adjuvant. The DENV envelope protein (E), the main target for neutralizing immune responses, has three conformational domains. The immunoglobulin-like and independently folding domain III (DIII) contains epitopes that elicit highly specific neutralizing antibodies.

Reuse Permissions
  • 2.1 MB application/pdf

    Download count: 0

    Details

    Contributors
    Date Created
    • 2015
    Resource Type
  • Text
  • Collections this item is in
    Note
    • Partial requirement for: M.S., Arizona State University, 2015
      Note type
      thesis
    • Includes bibliographical references (pages 84-87)
      Note type
      bibliography
    • Field of study: Biology

    Citation and reuse

    Statement of Responsibility

    by Indira Harahap

    Machine-readable links